Onesource Specialty Pharma Receives In-Principle Approval for Unit II Expansion in Bengaluru
Onesource Specialty Pharma Limited has received in-principle approval from the Government of Karnataka for the expansion of its flagship Unit II facility. This approval pertains to the company's investment proposal under the Karnataka Industrial Policy (KIP) 2025-30, securing incentives and concessions for the project.The expansion is slated for the company's Unit II facility located at Obadenahalli, 2nd Phase, KIADB Industrial Area, Doddaballapur Taluk, Bengaluru Rural District. The approval followed the consideration of the company’s proposal during the 67th State High Level Clearance Committee (SHLCC) meeting, which was held on April 13, 2026.
The company formally received the Government Order bearing No. CI 120 SPI 2026 on May 15, 2026, which was dated May 12, 2026.
The expansion represents a significant milestone in Onesource Specialty Pharma Limited’s growth strategy. Unit II is recognized as a flagship facility, and the proposed enhancement of its unit is expected to substantially boost the company’s manufacturing capacities to service global partners.
For quick reference, the key details regarding the approval process are outlined below:
| Detail | Information |
|---|---|
| Authority | Government of Karnataka |
| Policy Covered | Karnataka Industrial Policy (KIP) 2025-30 |
| Project | Unit II Expansion |
| Location | Obadenahalli, KIADB Industrial Area, Bengaluru Rural District |
| SHLCC Meeting Date | April 13, 2026 |
| Government Order No. | CI 120 SPI 2026 |
| GO Date | May 12, 2026 |
| Company Receipt Date | May 15, 2026 |
ONESOURCE Stock Price Movement
On Friday, Onesource Specialty Pharma Limited shares edged higher, closing at ₹1834.8, marking a 0.72% gain. The stock saw 255,649 shares traded during the session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.